Skip to content

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag
- Arena will receive $800M upfront, and is eligible to receive low double-digit tiered royalties, plus up to $400M in milestone payments - United Therapeutics will receive exclusive, worldwide rights to ralinepag - a potential best-in-class agent for the treatment of pulmonary arterial hypertension
View HTML
Toggle Summary Arena Pharmaceuticals Presented Preclinical Data for APD418 in Development for Treatment of Decompensated Heart Failure at American Heart Association Scientific Sessions
SAN DIEGO , Nov. 13, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented preclinical data for its recently announced investigational compound, APD418, a first-in-class calcium-independent myofilament derepressor (CMD), ß3 adrenergic receptor (AdrR) selective antagonist, at
View HTML
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2018 Financial Results
- Ralinepag open-label extension data demonstrated durable, long-term improvements in both PVR and 6MWD - Olorinab positive Phase 2a data for the treatment of pain associated with Crohn's disease; all patients with evaluable data at week 8 exhibited a pre-defined clinical improvement SAN DIEGO ,
View HTML
Toggle Summary Arena Pharmaceuticals to Release Third Quarter 2018 Financial Results and Provide Corporate Update on November 7
SAN DIEGO , Oct. 31, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its third quarter 2018 financial results and provide a corporate update on Wednesday, November 7, 2018 , after the close of the U.S. financial markets.
View HTML
Toggle Summary Arena Pharmaceuticals Presented Phase 2 Clinical Data for Etrasimod in Ulcerative Colitis at the American College of Gastroenterology Annual Meeting
SAN DIEGO , Oct. 8, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from its OASIS Phase 2 clinical study for its investigational drug candidate etrasimod, a next-generation, oral, S1P receptor modulator with optimized activity being evaluated in
View HTML
Toggle Summary Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension
- Ralinepag demonstrated durable, long-term improvements in both PVR and 6MWD - Favorable long-term tolerability profile demonstrated SAN DIEGO , Oct. 2, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive data from a planned interim analysis of the ongoing
View HTML
Toggle Summary Arena Pharmaceuticals Reports Positive Phase 2a Results for Olorinab in Patients with Abdominal Pain Associated with Crohn's Disease
- Olorinab demonstrated a statistically significant improvement in abdominal pain over 8 weeks of treatment - All patients with evaluable data at week 8 exhibited a pre-defined clinical response of ≥30% change from baseline in AAPS - Treatment effects were demonstrated early and were consistent
View HTML
Toggle Summary Arena Pharmaceuticals to Host R&D Day on October 4 in New York City
SAN DIEGO , Sept. 21, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will host an R&D Day to outline key catalysts and new information on the clinical programs for its potentially first- or best-in-class late-stage investigational compounds:
View HTML
Toggle Summary Arena Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO , Sept. 20, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences: Cantor Global Healthcare Conference – Presenting on Tuesday, October 2 , at 1:40 p.m.
View HTML
Toggle Summary Arena Pharmaceuticals Presents Preclinical Data for Olorinab at International Association for the Study of Pain World Congress
SAN DIEGO , Sept. 17, 2018 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that results from preclinical studies of its investigative drug candidate olorinab, a peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB 2 ) in development
View HTML